AbbVie partners with Iambic to accelerate AI-driven small-molecule drug discovery

Iambic will receive an upfront payment, success-based milestone payments and tiered royalties on net sales from products generated under the deal.

AbbVie entered a multi-year collaboration with Iambic to accelerate AI-driven discovery of small-molecule drugs across immunology, neuroscience and oncology.

The partnership applies Iambic’s AI platform to improve hit identification efficiency, aiming to shorten development timelines for first-in-class or best-in-class candidates.